BD Introduces UltraCor Twirl Markers for Breast Biopsy
Medical technology leader BD (Becton, Dickinson and Company) has officially introduced its UltraCor Twirl breast tissue markers in India. These advanced devices mark suspicious breast lesions during or after a percutaneous biopsy procedure. Consequently, clinicians can track pathology sites with high precision throughout diagnostic and therapeutic journeys.
Clinical Role of Breast Tissue Markers in Oncology
Breast cancer management frequently requires complex, multi-step pathways. For example, patients often undergo neoadjuvant systemic therapy before definitive surgical resection. In addition, chemotherapy can shrink or completely eliminate palpable or radiographically visible target tumors. Without reliable localization, surgeons face substantial challenges in identifying the initial tumor bed. Therefore, reliable breast tissue markers provide a permanent physical landmark within soft tissue and axillary lymph nodes. Furthermore, they facilitate targeted excision and prevent unnecessary tissue removal during breast-conserving surgery.
Design Features of UltraCor Twirl Markers
The UltraCor Twirl marker incorporates an engineered nitinol ring architecture. This polymer-free configuration promotes self-incorporation into surrounding tissue. As a result, the device markedly reduces the risk of post-biopsy marker migration. Additionally, it offers multi-modal visibility across ultrasound, digital mammography, and magnetic resonance imaging (MRI). Interventional radiologists can readily verify marker placement immediately after biopsy. Moreover, surgical teams can achieve precise preoperative wire-free or wire-guided localization under sonographic guidance.
Improving Breast Cancer Care Across India
The availability of advanced localization technology addresses a critical need in India's expanding oncology sector. Specifically, earlier tumor detection and increasing use of breast-conserving therapy demand reliable lesion tracking. When clinicians accurately mark target sites, multidisciplinary oncology teams make better therapeutic choices. Consequently, patients experience fewer re-excisions and achieve superior cosmetic outcomes. BD aims to support Indian healthcare providers with reliable tools that elevate standards of procedural precision.
Frequently Asked Questions
Q1: Why are breast tissue markers used during a biopsy?
Clinicians deploy these markers to permanently identify biopsy locations. Consequently, surgical teams can locate the original tumor site even if neoadjuvant therapy eliminates all visible tumor mass.
Q2: What makes the UltraCor Twirl marker distinct?
The marker features a nitinol ring design that prevents displacement. Additionally, it ensures clear visibility across mammography, ultrasound, and MRI without relying on polymer carriers.
Q3: Can clinicians track the marker across different imaging modalities?
Yes, the device provides distinct radiographic and sonographic contrast. Therefore, radiologists and surgeons can monitor lesion sites accurately during follow-up imaging and surgical planning.
References
- BD launches UltraCor Twirl breast tissue markers in India - ETHealthworld
- Sonographic visibility of the UltraCor Twirl tissue marker - Breast Disease Journal
- UltraCor Twirl Breast Tissue Marker Product Specifications - Becton, Dickinson and Company
